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Regulatory peptides and their analogs are being extensively
investigated as radiopharmaceuticals for cancer imaging and
therapy. Receptors of the cholecystokinin family have been
shown to be overexpressed in different types of neuroendocrine
tumors. The purposes of this study were to evaluate the chole-
cystokinin octapeptide amide (CCK8) peptide tagged with a
diethylenetriaminepentaacetic acid derivative (DTPAGlu) and to
test whether a 111In-labeled conjugate (111In-DTPAGlu-G-CCK8,
a derivative containing the chelating agent DTPAGlu bound
through a glycine linker at the N-terminal end of the bioactive
peptide CCK8) is suitable for cholecystokinin-B receptor
(CCKBR) imaging. Methods: CCK8 was synthesized by solid-
phase techniques and covalently coupled to DTPAGlu through a
glycine linker at its amino terminus. The compound was labeled
with 111In. The radiochemical purity and stability of the com-
pound were assessed by chromatographic methods. NIH-3T3
and A431 cells overexpressing CCKBR were used to charac-
terize the in vitro properties of the compound. Nude mice bear-
ing control and CCKBR-overexpressing A431 xenografts were
used as an in vivo model. Results: DTPAGlu-G-CCK8 showed
rapid and efficient labeling with 111In. The radiolabeled conju-
gate showed specific binding to both cell lines overexpressing
CCKBR. Binding was saturable, with a dissociation constant of
20 nmol/L in both cell systems. Both cell lines showed inter-
nalization of the ligand after interaction with the receptor. Bio-
distribution studies showed rapid localization of 111In-DTPAGlu-
G-CCK8 on CCKBR-overexpressing A431 xenografts that was
severalfold higher than that on control tumors at all time points
tested. Unbound activity showed rapid clearance of over 80%
through the kidneys by 30 min after injection. The labeled pep-
tide conjugate was very stable in serum but showed a rapid
breakdown after injection. Incubation with kidney homogenates
suggested that most breakdown occurred in the kidneys, favor-
ing the clearance of unbound activity. Conclusion: Our findings
indicate that the in vitro and in vivo characteristics of 111In-
DTPAGlu-G-CCK8 are favorable for CCKBR imaging, as the
peptide shows high-affinity binding to the receptor, is internal-
ized in CCKBR-expressing cells, and shows avid uptake in
CCKBR-overexpressing xenografts, with rapid clearance of un-
bound radioactivity through the kidneys. Furthermore, the ease
of synthesis, high labeling efficiency, and chemical stability of
DTPAGlu make this chelating moiety an ideal candidate for
widespread use in peptide radiolabeling for nuclear medicine
applications.
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Several receptor systems are being evaluated for the
development of peptide-based radiopharmaceuticals for di-
agnostic and therapeutic purposes (1). This field is of par-
ticular interest for applications in oncology. Many of these
receptor systems have been shown to be overexpressed in
particular types of human cancers. The naturally occurring
ligands for these receptors are, in many instances, small
peptides. The sequences and interactions of these peptides
with their specific receptors can be structurally character-
ized, and peptide derivatives can be designed and synthe-
sized to bear a chelating group for a radiometal. The prop-
erties of the peptide derivative as a radiopharmaceutical
then can be tested. An excellent example of the successful
clinical application of a peptide–receptor system has been
the use of the radiolabeled somatostatin analog octreotide,
which has been used in several clinical studies to identify
tumors and other pathologic conditions in which specific
subtypes of the somatostatin receptor are overexpressed (2).
The vasoactive intestinal peptide receptor (3) also has been
evaluated for similar applications. Several potential receptor
systems that can be used as molecular targets are under
investigation (4)
We have focused on the cholecystokinin (CCK) family of
receptors. Two major CCK receptor subtypes have been
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identified (CCKAR and CCKBR). CCKBR also is the gas-
trin receptor, which promotes acid secretion in the fundal
mucosa of the stomach. These receptors show physiologic
distributions in several different tissues, with rather selec-
tive expression of one or the other subtype. The CCKAR
subtype is expressed in the pancreas, where it has been
found to be involved in enzyme secretion in pancreatic acini
and insulin secretion from islet cells. It also is found in the
gallbladder and other areas of smooth muscle in the gastro-
intestinal tract, in the gastric mucosa, and in certain areas of
the central nervous system, such as vagal afferent neurons.
On the other hand, CCKBR is expressed throughout the
central nervous system and in various cell types in the
gastric mucosa, including parietal cells (responsible for acid
production), chief cells (responsible for pepsinogen produc-
tion), and enterochromaffin-like cells (producing histamine)
(5). The overexpression of both of these receptor subtypes
in certain human tumors has been demonstrated (6).
CCKAR has been found to be overexpressed in several
pancreatic adenocarcinomas and, to a lesser extent, in gas-
troenteropancreatic tumors. CCKBR has been found to be
overexpressed in a large percentage of medullary thyroid
cancers (MTCs), in other tumors of neuroendocrine origin
(such as small-cell lung cancers), and gastroenteropancre-
atic tumors. It also has been found in stromal ovarian
cancers, which are rather rare. Several cancer cell lines
derived from human pancreatic adenocarcinomas have been
found to express CCKAR. CCKBR has been found in the rat
pancreatic cell line AR42J and in other cell lines, including
those derived from medullary thyroid carcinoma, such as
the human cell line TT.
Given the particularly high incidence of CCKBR over-
expression in certain neuroendocrine tumors, such as MTCs
(90%) (6), CCKBR-directed radiopharmaceuticals may
be more successful than currently available somatostatin
analogs in the imaging and treatment of these cancer types.
For this reason, several CCK and gastrin derivatives have
been characterized over the past few years for the purpose
of in vivo receptor targeting. Behr et al. initially evaluated
radioiodinated gastrin I as a radiopharmaceutical (7); they
could indeed specifically target CCKBR in a xenograft
model of human medullary thyroid carcinoma (TT cells)
and in a patient with metastatic MTC. The same animal
model was used to screen several iodinated gastrin and CCK
derivatives (8,9). This extensive screening led to the use of
minigastrin for further preclinical and clinical development;
diethylenetriaminepentaacetic acid (DTPA)–coupled deriv-
atives of this peptide have been characterized (10,11). Reubi
et al. described several DTPA and dodecanetetraacetic acid–
coupled CCK analogs (12) with a high affinity for CCKBR.
One of these analogs, DTPA(D-Asp26,Nle28,31)CCK(26–33),
has been characterized in a rat tumor model (13) and in a
clinical trial in patients with MTCs (14).
Among the several biologically active forms of CCK, the
C-terminal CCK octapeptide amide (CCK8) is capable of
binding both receptors, although the sulfated form of CCK8
(with a sulfate moiety on the Tyr27 side chain) is 1,000-fold
more active than nonsulfated CCK8 in binding CCKAR
(15). Nonsulfated CCK8 therefore displays higher affinity
and selectivity for CCKBR. The bimolecular complexes of
CCK8 with the N-terminal extracellular arm of CCKAR
(16) and with the extracellular loops of CCKBR (17) have
been structurally characterized by high-resolution nuclear
magnetic resonance analysis and computational refinement.
The structures of both complexes indicate that modifications
at the N-terminal end of CCK8, obtained by introducing
chelating agents and their metal complexes, should not
affect the interaction of the peptide with CCKAR or
CCKBR.
Although most ligands that have been evaluated have
been demonstrated to specifically target CCKBR, there are
still some issues that can benefit from further study; there-
fore, it is worthwhile to assess the efficacies of different
compounds and different labeling approaches. Kidney up-
take and retention, for example, have been shown to be
extremely high, a situation that may cause problems for
kidney toxicity, particularly in therapeutic applications.
This problem appears to be significant with DTPA-coupled
minigastrin (8,9) but less evident with DTPA-coupled CCK
derivatives, such as sulfated CCK8 (8) and DTPA(D-
Asp26,Nle28,31)CCK(26–33) (13). Another issue being ad-
dressed is how to improve the kinetic stability of DTPA
conjugates to prevent transchelation of the radiometal after
injection. In particular, one objective is to allow more
secure coordination of therapeutic nuclides, such as 90Y
(11). This radionuclide displays a high level of accumula-
tion in bone and bone marrow toxicity when dissociated
from its chelating group.
On these bases, we have taken a different approach to
targeting CCKBR. We have used a native nonsulfated
CCK8 peptide sequence bearing a recently described DTPA
derivative, the chelating agent DTPAGlu (18), coupled to
the N terminus of the peptide during solid-phase synthesis.
The use of this novel chelating moiety has allowed us to
obtain a peptide conjugate having 5 carboxyl groups (as
opposed to the 4 normally available with conventional
DTPA labeling) and 3 amino groups available for radio-
metal coordination. A glycine residue has been introduced
as a spacer between the chelating agent and the biologically
active CCK8 peptide. The combination of the CCK8 pep-
tide sequence and the DTPAGlu moiety should allow us to
obtain a lower level of retention of radioactivity in the
kidneys, as shown for other CCK8 peptides (8,13), and to
make use of a more stable chelating group. We have char-
acterized the properties of this compound as a radiophar-
maceutical by evaluating its binding specificity and affinity,
cellular internalization, and retention in 2 cell culture sys-
tems of CCKBR overexpression as well as its in vivo
biodistribution properties in xenograft-bearing nude mice.
We have also performed a detailed analysis of compound
stability.
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MATERIALS AND METHODS
Peptide Synthesis
DTPAGlu-G-CCK8 peptide conjugate synthesis was performed
by solid-phase techniques under standard conditions with a 9-flu-
orenylmethoxy carbonyl (Fmoc) strategy. The DTPAGlu pen-
taester, the chelating agent fully protected by tert-butyl (tBu)
groups on its carboxyl groups, with the exception of the carboxyl
group on the side chain of glutamic acid, N,N-bis[2-[bis[2-(1,1-
dimethylethoxy)-2-oxoethyl]-amino]ethyl]-L-glutamic acid 1-(1,1-
dimethylethyl)ester, was provided by Bracco Imaging SpA and
was used without further purification. Its synthesis is described
elsewhere (18). When the sequence Fmoc-Gly-Asp(OtBu)-
Tyr(tBu)-Met-Gly-Trp(Boc)-Met-Asp(OtBu)-Phe-resin was com-
pleted (OtBu is tert-butoxy; Boc is tert-butoxycarbonyl), the Fmoc
N-terminal protecting group was removed and the peptide resin
was transferred to a manual vessel for coupling of the DTPAGlu
pentaester.
The DTPAGlu pentaester was coupled to the Gly -amino
group by use of 2 equivalents of DTPAGlu pentaester, benzotri-
azole-1-yl-oxy-tris-pyrrolidinophosphonium hexafluorophosphate
(PyBoP) and 1-hydroxybenzotriazole (HOBt), and 4 equivalents of
N,N-diisopropylethylamine (DIEA) in a single coupling. The re-
action was performed by stirring the mixture in dimethylform-
amide (DMF) for 3 h. For deprotection and cleavage, the fully
protected DTPAGlu peptide resin was treated with trifluoroacetic
acid (TFA) containing triisopropylsilane (TIS) (2.0%), ethanedi-
thiol (EDT) (2.5%), and water (1.5%). DTPAGlu-G-CCK8 was
precipitated at 0°C by the dropwise addition of diethyl ether.
Purification of the crude mixture was performed by reversed-phase
(RP) high-pressure liquid chromatography (HPLC) with a C18
column; elution was done by use of H2O:0.1% TFA (A) and
CH3CN:0.1% TFA (B) linear gradients with 5%–95% B over 45
min at a flow rate of 1 mL/min. This step was followed by analytic
HPLC, which showed 97% purity (retention time, 24.6 min).
Mass spectra (matrix-assisted laser desorption ionization–time of
flight) confirmed the product identity (molecular weight, 1,566.8;
calculated, 1,566.0).
Radiolabeling
111In was purchased from Nycomed Amersham Sorin Srl in the
chemical form 111In-Cl3 (740 MBq/mL). The DTPAGlu-G-CCK8
peptide was dissolved in CH3CN:20% H2O at concentrations of
0.1–1 mmol/L. Before labeling was done, 111In-Cl3 was buffered
by the addition of 10 volumes of sodium citrate (0.3 mol/L). One
volume of the peptide solution then was mixed with 10 volumes of
111In-citrate, and the mixture was incubated for at least 1 h at room
temperature. Labeling efficiency was determined by silica gel
thin-layer chromatography with sodium citrate (0.3 mol/L) as the
eluent or RP HPLC performed with a model 305 system (Gilson),
an analytic C18 column (Vydac) connected to a model 170 radio-
detector (Beckman), and H2O:0.1% TFA and CH3CN:0.1% TFA
gradients that were slightly different from those described above
(5%–70% CH3CN:0.1% TFA over 31 min). The retention time of
111In-DTPAGlu-G-CCK8 was 22.0 min.
Cell Lines and Nude Mouse Xenograft Models
NIH-3T3 cells overexpressing human CCKBR (NIH-3T3-
CCKBR cells) through stable transfection were obtained from Dr.
Sue Watson (University of Nottingham, Nottingham, U.K.). These
cells originally were developed by Dr. Y. Matsui (University of
Kobe Medical School, Kobe, Japan) (19) and used with his per-
mission. A431 cells were obtained from the American Type Cul-
ture Collection. A431 is a human epidermoid carcinoma cell line
that has been shown to yield subcutaneous tumors with a high
efficiency in immunologically incompetent mice (20). All cells
were grown in a humidified atmosphere containing 5% CO2 and
95% air at 37°C in Dulbecco modified Eagle medium containing
glucose (4.5 g/L) and supplemented with 10% heat-inactivated
fetal bovine serum (GibcoBRL, Life Technologies). To obtain
A431 cells overexpressing CCKBR (A431-CCKBR cells), com-
plementary DNA for the receptor was generated by reverse tran-
scriptase PCR of total RNA obtained from NIH-3T3-CCKBR
cells. Primers were designed on the basis of the published se-
quence of human CCKBR (GenBank accession number L07746)
to amplify the region between nucleotides 163 and 1,509, contain-
ing the full coding sequence. The PCR product then was cloned
into vector pCR3.1 (Invitrogen) by use of a eukaryotic TA cloning
kit (Invitrogen). The plasmid was sequenced, linearized, and trans-
fected into A431 cells by use of dioleoyltrimethylammonium
propane liposomal transfection reagent (Roche Molecular Bio-
chemicals). Transfectants were obtained after 2 wk of selection in
medium containing the neomycin analog G418 (500 g/mL; Gib-
coBRL). One positive transfectant and one control transfectant
(transfected with vector pCR3.1 alone) were isolated for further
analysis.
In Vitro Cellular Assays
All in vitro cellular assays were performed with cells that had
been plated at a density of 100,000–200,000 cells per well in
12-well plates 2 or 3 d before the experiments. These conditions
allowed for the cells to be almost confluent at the time of the
assays. Experiments aimed at assessing the specificity of the in-
teraction were performed by comparing cell-associated activity
after incubation of the radiolabeled peptide with A431-CCKBR
cells and A431 control cells and with A431-CCKBR cells in the
presence of excess unlabeled peptide. Triplicate wells were incu-
bated with known amounts of radiolabeled peptide for different
times at 37°C. After incubation, cells were washed with phos-
phate-buffered saline (pH 7.4) (PBS) and then recovered by
trypsinization. Cell-associated radioactivity and total radioactivity
were determined with a Wizard -counter (Wallac Oy). The
amount of bound compound was normalized for protein content,
which was determined by use of a commercially available kit
(Bio-Rad Laboratories) after cells were solubilized in 1N NaOH.
To assess the binding affinity of the compound, duplicate wells
were incubated with serial dilutions of 111In-DTPAGlu-G-CCK8 in
culture medium at 4°C for 1 h; concentrations ranged from 0.05 to
50 nmol/L. To assess nonspecific binding, a 100- to 1,000-fold
excess of unlabeled peptide was added to some of the wells. For all
experiments, cell-associated radioactivity was recovered from the
wells by trypsinization of cells after 2 rapid washes in ice-cold
PBS. Radioactivity then was counted and normalized for the
number of cells, and nonspecific binding was subtracted. Binding
curves were analyzed with a Macintosh computer and Kaleida-
graph software (Abelbeck Software, version 3.0.5; distributed by
Synergy Software). Dissociation constants (Kds) and the apparent
numbers of binding sites per cell (Bmax) were derived by fitting the
data to the following equation: bound (Bmax  [111In-DTPAGlu-
G-CCK8])/(Kd  [111In-DTPAGlu-G-CCK8]).
Cellular internalization was determined by comparing differ-
ences in the accumulation of the compound incubated with A431-
CCKBR cells at 4°C, the temperature at which most metabolic
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processes are blocked, and at 37°C, at which all metabolic pro-
cesses, including receptor internalization, are active. Cells were
incubated with 111In-DTPAGlu-G-CCK8 (20 nmol/L) at the 2
temperatures for 60 and 120 min. After 120 min of incubation,
some wells were rinsed with PBS to remove unbound radioactivity
and then were incubated for an additional 60 min at 4°C with
unlabeled peptide (30 mol/L) to displace any surface-bound
radioactivity. Radioactivity associated with cells was determined
after unbound radioactivity was washed away and then was nor-
malized for protein content.
Retention of the cell-associated label was assessed by allowing
A431-CCKBR cells to accumulate 111In-DTPAGlu-G-CCK8 at
37°C for 2 h, washing away unbound radioactivity, and replacing
the cells in the incubator with fresh culture medium. After different
times, cell-associated radioactivity was determined as described
above.
Biodistribution Studies
Mice bearing xenografts of A431-CCKBR cells and A431 con-
trol cells were generated by injection of 100 L of the respective
cell suspensions at a density of 2  107 cells per milliliter in PBS
into opposite flanks of 6-wk-old CD-1 nude mice (weight, 17–23
g). Tumors were allowed to grow for 10–14 d. The final tumor
weights were between 0.5 and 1 g at the time of the biodistribution
and imaging experiments. The time courses for tissue and tumor
distributions of 111In-DTPAGlu-G-CCK8 were determined after
injection into the lateral tail vein of 1.85 MBq (50 Ci, 0.4–1
g or 0.2–0.5 nmol of peptide) of labeled peptide per mouse. At
least 5 animals per time point were used. The animals were killed
at 30, 120, and 240 min after injection. Blood, lung, liver, spleen,
kidney, stomach, intestine, muscle, and xenograft samples were
weighed, and radioactivity was determined with the -counter.
Counts for dilutions of the injected compound were obtained
simultaneously for accurate determination of the injected dose.
The relative amounts of radioactivity in the organs were calculated
and expressed as the percentage injected dose (%ID) per gram of
tissue normalized for a 20-g mouse. For some animals, pinhole
-camera imaging was performed after the mice were sacrificed to
visualize CCKBR-positive tissues.
Compound Stability
The stability of 111In-DTPAGlu-G-CCK8 was tested by incu-
bating the compound with mouse serum for 1 h at 37°C or by
injecting the compound into a nude mouse and recovering blood
samples at 30 and 120 min after injection. The blood samples were
centrifuged to recover serum, and all samples were extracted with
an equal volume of CH3CN to precipitate high-molecular-weight
proteins. The resulting soluble fraction was subjected to RP HPLC,
and radioactivity was assessed directly with the radiodetector;
alternatively, when count rates were too low, 1-min fractions were
collected and assayed in the -counter. Similarly, experiments
aimed at determining the tissue metabolism of the compound were
performed with homogenates obtained from freshly prepared
mouse tissue samples. Aliquots of 111In-DTPAGlu-G-CCK8 were
incubated with the homogenates for times ranging from 0 to 60
min, extracted with CH3CN, and analyzed by RP HPLC as de-
scribed above.
To assess the transchelation of 111In to iron-binding proteins in
the serum, such as transferrin, the labeled peptide was incubated
with mouse or fetal bovine serum for up to 24 h at 37°C or
recovered after injection as described above. Serum and plasma
from blood samples were subjected to size exclusion chromatog-
raphy with Sephadex G-50 spin columns (Roche). Controls for
these experiments consisted of freshly labeled 111In-DTPAGlu-G-
CCK8 and fetal bovine serum (GibcoBRL) incubated with small
amounts of 111In-Cl3 for 2 h at 37°C.
RESULTS
Synthesis of DTPAGlu-G-CCK8
After standard solid-phase peptide synthesis of the CCK8
peptide, DTPAGlu was coupled to the N terminus of the
resin-bound peptide according to the schematic representa-
tion shown in Figure 1. This coupling step was very effi-
cient; however, the subsequent deprotection reaction re-
quired a prolonged time to ensure complete removal of the
tBu protecting groups. Final HPLC purification resulted in
high purity and yields of the DTPAGlu-G-CCK8 conjugate.
FIGURE 1. Schematic representation of
coupling of the DTPAGlu moiety to the
resin-bound G-CCK8 peptide. Subsequent
deprotection yields the final compound,
which is ready for radiolabeling.
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Radiolabeling and Quality Control
Rapid and efficient labeling was obtained as early as 30
min after the addition of 111In to the compound. Typical
yields were 97%, as determined by RP HPLC, at specific
activities ranging from 4 to 9 GBq/mol (100–250 Ci/
mmol). The elution pattern was identical to that observed
with the conjugate in the presence of stable indium and
monitored by UV absorption. No purification was needed
after radiolabeling for all subsequent experiments (Fig. 2A).
Cell Binding and Internalization
111In-DTPAGlu-G-CCK8 showed rapid specific binding
to both NIH-3T3-CCKBR cells and A431-CCKBR cells.
Figure 2B shows a time course experiment with NIH-3T3-
CCKBR and NIH-3T3 control cells incubated with nonsat-
urating concentrations of 111In-DTPAGlu-G-CCK8. The ex-
periment showed rapid initial binding of the compound to
CCKBR-expressing cells and slowly increasing cell-associ-
ated amounts over time. The level of nonspecific binding, as
assessed by incubation of the compound with non–receptor-
expressing cells or with receptor-expressing cells in the
presence of a 100-fold excess of unlabeled peptide, was
very low. Similar results were obtained with A431-CCKBR
cells and A431 control cells (data not shown). Figure 3
shows saturation curves for the compound on 2 CCKBR-
overexpressing cell lines. These experiments were per-
formed at 4°C to block receptor internalization and thus
measure only ligand–receptor interactions. In both cell sys-
tems, binding was saturable, with Kds on the order of 20
nmol/L. A431-CCKBR cells had a larger number of recep-
tors (approximately 4.7  106 sites per cell compared with
1.6  106 sites per cell for NIH-3T3-CCKBR cells).
To evaluate whether the peptide was internalized by the
cells, we performed parallel experiments in which A431-
CCKBR cells were incubated with 111In-DTPAGlu-G-
CCK8 (20 nmol/L) at 4°C (internalization blocked) or 37°C
(internalization active) (Fig. 4A). There was a progressive
FIGURE 2. (A) Radioactive trace of RP
HPLC analysis after labeling for 60 min at
room temperature. 111In-DTPAGlu-G-CCK8
shows a retention time of approximately 22
min on the CH3CN:H2O gradient. Unincorpo-
rated 111In, which has a retention time of
approximately 3 min, is barely detectable. (B)
Specificity of interactions of 111In-DTPAGlu-
G-CCK8 with NIH-3T3-CCKBR cells and
control cells. There is a progressive increase
of cell-associated activity in receptor-posi-
tive cells incubated with the radioactive pep-
tide alone (Œ). Receptor-negative cells (F)
and receptor-positive cells incubated with
excess unlabeled peptide (f) show very little
interaction with the radiolabeled peptide.
There were 3 samples per time point; error
bars indicate SDs.
FIGURE 3. Binding of 111In-DTPAGlu-G-
CCK8 on NIH-3T3-CCKBR cells (A) and
A431-CCKBR cells (B) at 4°C. Both cell
lines showed saturable binding of the pep-
tide, with equivalent Kds (22 	 11 nmol/L
[mean 	 SD] for NIH-3T3-CCKBR cells;
23 	 4 nmol/L for A431-CCKBR cells).
A431-CCKBR cells had higher Bmax values
(1.6  106 	 0.4  106 sites per cell
[mean 	 SD] for NIH-3T3-CCKBR cells;
4.7  106  0.4  106 sites per cell for
A431-CCKBR cells). There were 2 samples
per concentration; error bars indicate SDs.
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accumulation of radiolabel in cells incubated at 37°C with
labeled peptide alone, whereas the levels of cell-associated
radioactivity were constant in cells incubated at 4°C for 60
and 120 min, suggesting that internalization occurred to
some extent at 37°C. Coincubation with excess cold peptide
produced very low levels of cell-associated activity, con-
firming the specificity of the interaction. After incubation
for 120 min with labeled peptide alone, cells were incubated
with excess cold peptide for 60 min at 37°C. A large portion
of the radioactivity (85%) was displaced by the cold
peptide in cells incubated at 4°C, whereas very little
(10%) was displaced in cells previously incubated at
37°C; these results indicated that the compound indeed had
been internalized to a large extent in cells incubated at
37°C. Similar results were obtained with NIH-3T3-CCKBR
cells (data not shown). The release of cell-associated radio-
activity (Fig. 4B) was biexponential, with an early, rapid
component likely attributable to the effect of dilution of the
ligand–receptor complex after the addition of fresh medium
and a later, slower component likely attributable to the
release of radiolabel internalized in cells.
Biodistribution and Imaging
The data obtained in the biodistribution experiments are
displayed in Figure 5. The uptake of 111In-DTPAGlu-G-
CCK8 into A431-CCKBR xenografts was higher than that
into A431 control tumors at all time points tested, with a
progressive increase in the target-to-nontarget ratio (recep-
tor-positive vs. receptor-negative tumors) from 3.3:1 at 30
min after injection to 5.5:1 at 120 min and 10:1 at 240 min.
The only organs showing uptake higher than that in
CCKBR-positive xenografts were the kidneys, which also
showed a progressive release of radioactivity over time.
Uptake in the stomach was slightly higher than that in the
rest of the gastrointestinal tract. The accumulation of 111In-
DTPAGlu-G-CCK8 in the remaining organs, including the
liver, was negligible and appeared to decrease in parallel to
FIGURE 4. Cellular internalization and release of 111In-DTPAGlu-G-CCK8 for A431-CCKBR cells. (A) Internalization. Cells were
incubated at 4°C () and 37°C (f) for 60 and 120 min with radiolabeled peptide (20 nmol/L). Excess unlabeled peptide was added
during the 2-h incubation (third set of bars from left) or after the 2-h incubation and after washes in PBS to displace label on the
cell surface (fourth set of bars from left). There is a progressive increase of cell-bound activity at 37°C, whereas a constant level
is observed at 4°C. Coincubation with cold ligand produced a very low level of binding under both conditions. The addition of cold
ligand after the 2-h incubation displaced most of the radioactivity from cells incubated at 4°C, consistent with the ligand being on
the cell surface, whereas very little displacement was observed for cells incubated at 37°C, indicating that the label was in an
intracellular compartment in these cells. (B) Release. Cells incubated at 37°C for 2 h were rinsed with PBS. Fresh medium was
added, and cell-associated radioactivity was determined at the indicated times. There were 3 samples per time point; error bars
indicate SDs.
FIGURE 5. Biodistribution of 111In-DTPAGlu-G-CCK8 after in-
travenous injection. Organ-associated radioactivity is ex-
pressed as the %ID per gram of tissue normalized for a 20-g
mouse. There were at least 5 samples per time point; error bars
indicate SDs. GI  gastrointestinal.
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blood clearance of the compound. More than 80% of the
injected activity was cleared through the kidneys by 30 min.
The pinhole -camera image obtained at 2 h after injection
(Fig. 6) showed marked accumulation of the compound in
the CCKBR-positive tumor and in the kidneys and very low
uptake in the control tumor.
Stability and Metabolites
Because the overall clearance of radioactivity was ex-
tremely rapid, we evaluated the stability of the peptide
conjugate under different conditions. Incubation of the pep-
tide in mouse serum for 1 h produced almost no effect on
the compound (Fig. 7A, top trace). On the other hand,
radioactivity recovered from the blood at 30 and 120 min
after injection showed a marked breakdown of the starting
compound to hydrophilic by-products, and the starting ma-
terial was no longer detectable (Fig. 7A, bottom 2 traces).
Gel filtration analysis of blood samples obtained at the same
time points showed that 99% of the radioactivity was
retained in the included volume of the spin columns. This
result suggests that among the metabolites generated after
injection, there is no unbound 111In. In fact, in control
experiments, incubation of 111In-Cl3 in serum for the same
times caused most (60%) of the radioactivity to be ex-
cluded from the resin, consistent with the transchelation of
the radiometal to transferrin or other metal-binding proteins.
Radiolabeled peptide incubated at 37°C in fetal bovine
serum for up to 24 h showed very little transchelation
(6%	 0.7% [mean	 SD] at 24 h) of 111In to high-molecular-
weight proteins, indicating very high chelate stability. Because
metabolism in the organs rather than in serum appears to play
a major role, the compound was incubated with tissue homog-
enates obtained from the liver and kidneys (Figs. 7B and 7C).
Incubation with homogenates from both of these organs pro-
FIGURE 6. Pinhole -camera image obtained at 2 h after
injection of 111In-DTPAGlu-G-CCK8. Avid accumulation of the
peptide was seen in a CCKBR-positive xenograft (right thigh)
but not in a control tumor (left thigh). Hot spots in the abdomen
are consistent with kidney accumulation.
FIGURE 7. (A) RP HPLC analysis of 111In-DTPAGlu-G-CCK8 incubated for 1 h in serum (top trace) and radioactivity recovered
from blood samples taken at different times after injection into a nude mouse (bottom 2 traces). The compound is very stable in
serum but appears to be rapidly metabolized after injection to more hydrophilic compounds. The small amount of radioactivity in
the blood samples taken after injection required the use of a fraction collector and -counting. (B and C) RP HPLC analysis of
111In-DTPAGlu-G-CCK8 incubated with tissue homogenates of liver (B) and kidneys (C). Homogenates were freshly prepared and
incubated on ice. Radiolabeled peptide was added to the homogenates and either immediately extracted with CH3CN (0 min) or
incubated at 37°C for the indicated times. A breakdown of the peptide to more hydrophilic forms appears to be more rapid and
prominent in the kidneys.
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duced degradation of the compound that appeared to be more
rapid and complete in kidney extracts.
DISCUSSION
We have characterized the in vitro and in vivo properties
of 111In-DTPAGlu-G-CCK8, a derivative containing the
chelating agent DTPAGlu bound through a glycine linker at
the N-terminal end of the bioactive peptide CCK8. Other
investigators already have demonstrated the feasibility of
using CCK8-based peptides to target CCKBR in vivo
(8,13). The novelty of our work involves the use of a new
DTPA derivative. There are 2 advantages to this approach.
First, the use of the chelating agent DTPAGlu allows a
peptide conjugate having 5 carboxyl groups and 3 amino
groups available for radiometal coordination to be obtained.
The 8 chelating functions constitute a coordinated set able
to yield stable metal complexes, in particular, with metal
ions in the 3 oxidation state. There is one more chelating
function beyond the coordinated set displayed by DTPA
directly bound to a peptide. The 8 functions displayed in the
coordinated set by our peptide conjugate are the same as
those used by DTPA alone to yield very stable complexes.
The additional coordinating moiety may provide better sta-
bility for chelating other radiometals of interest, such as 90Y,
which is used in therapeutic applications and is known to
form rather unstable complexes with conventional DTPA-
coupled peptides (21).
Second, the entire peptide conjugate is synthesized in the
solid phase, allowing high yields of the compound and high
purity of the raw product to be obtained. The final HPLC
purification step yields a well-characterized compound that
corresponds to the desired molecule. Up to now, most
peptide–chelate conjugates, as well as some DTPA-coupled
derivatives of CCK8 and gastrin and their analogs, have
been prepared by solution coupling of the chelating moiety
to the bioactive peptide (8). This procedure produces
potentially undesirable by-products and lower yields than
does chelator coupling during solid-phase synthesis,
which also has been described for coupling CCK8 analogs
to DTPA (12).
Radiolabeling of the compound was rapid and yielded a
high radiochemical purity (Fig. 2A), consistent with the
predicted high efficiency of the DTPAGlu moiety for coor-
dinating indium. The labeled compound displayed a specific
interaction with CCKBR in both of the cell lines that we
tested. Radiolabeled peptide bound to CCKBR-overex-
pressing cells was displaced easily by the addition of unla-
beled peptide. Binding to non–receptor-expressing cells was
negligible (Fig. 2B). The affinity of the interaction between
111In-DTPAGlu-G-CCK8 and CCKBR was adequate for use
in clinical applications. Kds on the order of 10
8 mol/L are
well within the acceptable range for receptor-binding radio-
pharmaceuticals (22).
One of the biologic features of G-protein–coupled recep-
tors, such as CCKBR, is that the receptor and the ligand are
internalized to intracellular compartments after interaction.
This mechanism constitutes the principal means by which
the cell limits the molecular signal provided by receptor
activation. For radiopharmaceutical application of peptides,
this mechanism provides higher levels of labeled material to
be associated with target cells through at least 2 mecha-
nisms. First, the ability to internalize and continuously turn
over the receptor population that is available on the cell
surface guarantees that there are always receptors on the cell
surface capable of interacting with the ligand present in the
extracellular space. Second, because the radiolabeled ligand
is internalized, it is removed from the equilibrium between
unbound compound and bound compound, thus increasing
target-associated radioactivity. Internalization also contrib-
utes to prolongation of the retention times of radiopharma-
ceuticals in the target organ, which are of particular interest
in therapeutic applications with radionuclides. Our com-
pound appears to be internalized to a large extent when
incubated with cells at 37°C (Fig. 4A) in both cell systems
tested. Furthermore, the retention time of the radiolabel in
cells appears to be sufficient for use of the compound in
clinical applications, and this feature likely is aided by the
fact that the compound is internalized (Fig. 4B).
In vivo evaluation of 111In-DTPAGlu-G-CCK8 showed
rapid and specific targeting of CCKBR-expressing xeno-
grafts (Fig. 5). At all time points evaluated, there was a
severalfold-higher accumulation of radioactivity in these
xenografts than in control xenografts. Clearance of unbound
radioactivity was extremely rapid and occurred exclusively
via the urinary tract, with retention of a portion of the
injected radioactivity in the kidneys. There appears to be
virtually no clearance through the hepatobiliary system, a
great advantage, because such clearance produces low back-
ground activity in the gastrointestinal tract that may impair
the detection of CCKBR-overexpressing tumors in the ab-
domen. Nonspecific retention of radioactivity in other or-
gans is low. There is a slightly higher level of retention of
the compound in the stomach than in the rest of the gastro-
intestinal tract, consistent with higher concentrations of
CCKBR in specific areas of this organ. Imaging experi-
ments performed with 111In-DTPAGlu-G-CCK8 (Fig. 6)
confirm the suitability of the peptide conjugate for in vivo
applications. The low level of background activity and high
level of specific targeting of CCKBR-positive tumors are
evident in the scintigraphic image.
The in vitro stability of 111In-DTPAGlu-G-CCK8 in se-
rum is high, and the compound remains intact for prolonged
periods of incubation at 37°C. Blood samples drawn from
mice after injection of the compound, however, show the
presence of only circulating metabolites as early as 30 min
after injection (Fig. 7A). These observations suggest that
although the compound is stable enough in serum to reach
receptor-expressing tissues, it is also actively metabolized at
some level. We presume that such breakdown occurs in the
kidneys because, first, there is a high level of accumulation
of label in the kidneys in the biodistribution experiments
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(Fig. 5) and, second, the experiments performed with kid-
ney homogenates ex vivo show that enzymatic activities
present in the kidneys are capable of rapidly and thoroughly
metabolizing the peptide conjugate (Fig. 7C). Such rapid in
vivo metabolism of the radiolabeled peptide likely is a
major contributing factor for high target-to-nontarget ratios
in A431 xenografts, as it favors the rapid clearance of
unbound radioactivity. The hydrophilic breakdown products
generated are cleared rapidly through the urine, keeping
background radioactivity levels low. During this process,
there appears to be no breakdown of the 111In-DTPA com-
plex. In fact, the 111In appears to remain bound to the
chelating agent, as no generation of free 111In ions occurs.
The stability of the chelating moiety also contributes to
keeping background radioactivity levels low, as free 111In
would be retained on metal-binding proteins present in the
serum and would show slower clearance. Overall, the rapid
metabolism of the peptide conjugate and the stability of the
chelating moiety contribute to the achievement of low back-
ground radioactivity levels but to no hindrance of the ability
of the compound to bind specifically to CCKBR-expressing
tumors.
Kidney uptake of small peptides is a major concern, as
the kidneys are typically the critical organs for these types
of radiopharmaceuticals and for CCKBR-targeting peptides
as well. DTPA-coupled minigastrin derivatives (9,11) have
kidney retention values of 40–50 %ID/g in tumor-bearing
nude mice. These values are rather constant from 10 min
after injection up to 24 h. Reducing kidney accumulation
while maintaining good specific targeting would lower the
radiation dose absorbed by these organs. This situation
would be a major improvement, as concerns for nephrotox-
icity already have been raised in preliminary therapeutic
applications with 90Y (10). The retention in kidneys of our
compound progressively decreases over time (at 4 h, kidney
retention is 2.0 	 0.9 %ID/g [mean 	 SD]). However, no
definitive conclusions can be gathered by comparing tumor
uptake values, because different models were used and there
were differences in the numbers of receptors expressed and
other variables, such as vascular permeability and blood
flow. Our compound shows better relative CCKBR target-
ing; A431-CCKBR xenografts at 4 h show uptake of 1.4 	
0.9 %ID/g and a tumor-to-kidney ratio of 1:1.5. For 111In-
DTPA-minigastrin, uptake in TT xenografts has been re-
ported to be 4 %ID/g at 3 h after injection (9), with a
tumor-to-kidney ratio of 1:10, and 0.31 	 0.06 %ID/g at
4 h (11), with a tumor-to-kidney ratio of 1:160. 111In-
DTPA-sulfated CCK8 (8) has a much lower level of kidney
retention, 6 %ID/g at 4 h, and an uptake value of6 %ID/g
at 4 h in TT xenografts (1:1 tumor-to-kidney ratio); how-
ever, this compound has similar retention levels in other
organs, such as the lungs, liver, and spleen, and therefore
shows poor specific targeting and elevated background ac-
tivity levels. DTPA(D-Asp26,Nle28,31)CCK(26–33) (13) was
evaluated in a rat tumor model and showed good relative
targeting of CA20948 tumors (0.09 % ID/g at 24 h, com-
pared with 0.3 %ID/g in the kidneys); however, a later
evaluation in humans (14) showed high background activity
levels in scintigraphic images, with evidence of hepatobili-
ary clearance and relatively poor targeting of CCKBR-
positive structures, such as the stomach.
Improvement of the kinetic stability of DTPA-coupled
peptides for chelating indium and yttrium also has been
addressed as a way to advance this class of radiopharma-
ceuticals. Behe et al. recently showed that the stability of
111In-DTPA-minigastrin is improved greatly by the addition
of a D-Glu moiety adjacent to the chelating group (11). This
structure results in lower rates of indium transchelation to
proteins, although the exact mechanism by which this pro-
cess occurs still is not fully understood. DTPA-D-Glu-mini-
gastrin shows transchelation rates on the order of 7%–8%
after incubation for 24 h in serum; the rate for DTPA-
minigastrin is 25%. The transchelation rate that we ob-
tained (6% at 24 h in fetal bovine serum) is in the same
range as those reported for DTPA-D-Glu-minigastrin, indi-
cating that the DTPAGlu chelating moiety provides an
advantage in stability. Future studies will address the use of
this approach for the labeling, stability, and therapeutic
efficacy of 90Y-DTPAGlu-G-CCK8.
CONCLUSION
We have characterized the chemical, radiochemical, in
vitro, and in vivo biologic properties of 111In-DTPAGlu-G-
CCK8. The compound shows specific, high-affinity binding
and is internalized by CCKBR-expressing cells in vitro. The
specificity of the interaction of the compound with its re-
ceptor is maintained in applications in nude mice, showing
a high level of accumulation in CCKBR-positive xeno-
grafts, rapid renal clearance, and a low level of background
activity. Our findings indicate that 111In-DTPAGlu-G-CCK8
shows promise for clinical use in CCK receptor imaging and
has biodistribution characteristics more favorable than those
of previously described CCKBR-binding ligands. Further-
more, the ease of synthesis, high labeling efficiency, and
chemical stability of the 111In-DTPAGlu complex make this
an ideal candidate for use in other peptide-radiolabeling
applications.
ACKNOWLEDGMENTS
This work was funded by Ministero Universita´ e Ricersca
Scientifica e Tecnologica and Consiglio Nazionale delle
Ricerche, Progetto Strategico: Oncologia. The technical as-
sistance of Carmine Di Nuzzo is greatly appreciated. We are
grateful to Bracco Imaging SpA for providing the DTPAGlu
compound. We thank Silvio Aime for critical assessment of
the results obtained.
REFERENCES
1. Behr TM, Gotthardt M, Barth A, Behe M. Imaging tumors with peptide-based
radioligands. Q J Nucl Med. 2001;45:189–200.
2. Kwekkeboom D, Krenning EP, de Jong M. Peptide receptor imaging and therapy.
J Nucl Med. 2000;41:1704–1713.
EVALUATION OF 111IN-DTPAGLU-G-CCK8 • Aloj et al. 493
3. Virgolini I, Raderer M, Kurtaran A, et al. Vasoactive intestinal peptide-receptor
imaging for the localization of intestinal adenocarcinomas and endocrine tumors.
N Engl J Med. 1994;331:1116–1121.
4. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy.
Endocr Rev. 2003;24:389–427.
5. Wank SA. G protein-coupled receptors in gastrointestinal physiology. I. CCK
receptors: an exemplary family. Am J Physiol. 1998;274:G607–G613.
6. Reubi JC, Schaer JC, Waser B. Cholecystokinin(CCK)-A and CCK-B/gastrin
receptors in human tumors. Cancer Res. 1997;57:1377–1386.
7. Behr TM, Jenner N, Radetzky S, et al. Targeting of cholecystokinin-B/gastrin
receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and
therapeutic potential of radiolabelled gastrin. Eur J Nucl Med. 1998;25:424–430.
8. Behr TM, Behe M, Angerstein C, et al. Cholecystokinin-B/gastrin receptor
binding peptides: preclinical development and evaluation of their diagnostic and
therapeutic potential. Clin Cancer Res. 1999;5(suppl):3124s–3138s.
9. Behr TM, Jenner N, Behe M, et al. Radiolabeled peptides for targeting chole-
cystokinin-B/gastrin receptor-expressing tumors. J Nucl Med. 1999;40:1029–
1044.
10. Behr TM, Behe MP. Cholecystokinin-B/gastrin receptor-targeting peptides for
staging and therapy of medullary thyroid cancer and other cholecystokinin-B
receptor-expressing malignancies. Semin Nucl Med. 2002;32:97–109.
11. Behe M, Becker W, Gotthardt M, Angerstein C, Behr TM. Improved kinetic
stability of DTPA-DGlu as compared with conventional monofunctional DTPA in
chelating indium and yttrium: preclinical and initial clinical evaluation of radio-
metal labelled minigastrin derivatives. Eur J Nucl Med Mol Imaging. 2003;30:
1140–1146.
12. Reubi JC, Waser B, Schaer JC, et al. Unsulfated DTPA- and DOTA-CCK analogs
as specific high-affinity ligands for CCK-B receptor-expressing human and rat
tissues in vitro and in vivo. Eur J Nucl Med. 1998;25:481–490.
13. de Jong M, Bakker WH, Bernard BF, et al. Preclinical and initial clinical
evaluation of 111In-labeled nonsulfated CCK8 analog: a peptide for CCK-B
receptor-targeted scintigraphy and radionuclide therapy. J Nucl Med. 1999;40:
2081–2087.
14. Kwekkeboom DJ, Bakker WH, Kooij PP, et al. Cholecystokinin receptor imaging
using an octapeptide DTPA-CCK analogue in patients with medullary thyroid
carcinoma. Eur J Nucl Med. 2000;27:1312–1317.
15. Gigoux V, Maigret B, Escrieut C, et al. Arginine 197 of the cholecystokinin-A
receptor binding site interacts with the sulfate of the peptide agonist cholecys-
tokinin. Protein Sci. 1999;8:2347–2354.
16. Pellegrini M, Mierke DF. Molecular complex of cholecystokinin-8 and N-
terminus of the cholecystokinin A receptor by NMR spectroscopy. Biochemistry.
1999;38:14775–14783.
17. Giragossian C, Mierke DF. Intermolecular interactions between cholecystoki-
nin-8 and the third extracellular loop of the cholecystokinin-2 receptor. Biochem-
istry. 2002;41:4560–4566.
18. Anelli PL, Fedeli F, Gazzotti O, Lattuada L, Lux G, Rebasti F. L-Glutamic acid
and L-lysine as useful building blocks for the preparation of bifunctional DTPA-
like ligands. Bioconjug Chem. 1999;10:137–140.
19. Ito M, Iwata N, Taniguchi T, Murayama T, Chihara K, Matsui T. Functional
characterization of two cholecystokinin-B/gastrin receptor isoforms: a preferen-
tial splice donor site in the human receptor gene. Cell Growth Differ. 1994;5:
1127–1135.
20. Giard DJ, Aaronson SA, Todaro GJ, et al. In vitro cultivation of human tumors:
establishment of cell lines derived from a series of solid tumors. J Natl Cancer
Inst. 1973;51:1417–1423.
21. Fichna J, Janecka A. Synthesis of target-specific radiolabeled peptides for diag-
nostic imaging. Bioconjug Chem. 2003;14:3–17.
22. Eckelman WC. The application of receptor theory to receptor-binding and en-
zyme-binding oncologic radiopharmaceuticals. Nucl Med Biol. 1994;21:759–
769.
494 THE JOURNAL OF NUCLEAR MEDICINE • Vol. 45 • No. 3 • March 2004
